
A new request for information asks for comments on dose selection, safety monitoring, eligibility criteria, and oversight approaches to support the responsible development of ibogaine drug products.
Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017.
Schulman IRB announced its commercial institutional biosafety committee (IBC) service will launch in May 2017. The IBC service represents Schulman’s response to requests from research sponsors, CROs and institutions seeking an independent option for establishing IBCs when required by federal guidelines.
Read the full release






